Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 8:9:110.
doi: 10.1186/1748-717X-9-110.

Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway

Affiliations

Fractionated stereotactic radiosurgery for patients with skull base metastases from systemic cancer involving the anterior visual pathway

Giuseppe Minniti et al. Radiat Oncol. .

Abstract

Background: To analyze the tumor control, survival outcomes, and toxicity after stereotactic radiosurgery (SRS) for skull base metastases from systemic cancer involving the anterior visual pathway.

Patients and methods: We have analyzed 34 patients (23 females and 11 males, median age 59 years) who underwent multi-fraction SRS for a skull base metastasis compressing or in close proximity of optic nerves and chiasm. All metastases were treated with frameless LINAC-based multi-fraction SRS in 5 daily fractions of 5 Gy each. Local control, distant failure, and overall survival were estimated using the Kaplan-Meier method calculated from the time of SRS. Prognostic variables were assessed using log-rank and Cox regression analyses.

Results: At a median follow-up of 13 months (range, 2-36.5 months), twenty-five patients had died and 9 were alive. The 1-year and 2-year local control rates were 89% and 72%, and respective actuarial survival rates were 63% and 30%. Four patients recurred with a median time to progression of 12 months (range, 6-27 months), and 17 patients had new brain metastases at distant brain sites. The 1-year and 2-year distant failure rates were 50% and 77%, respectively. On multivariate analysis, a Karnofsky performance status (KPS) >70 and the absence of extracranial metastases were prognostic factors associated with lower distant failure rates and longer survival. After multi-fraction SRS, 15 (51%) out of 29 patients had a clinical improvement of their preexisting cranial deficits. No patients developed radiation-induced optic neuropathy during the follow-up.

Conclusions: Multi-fraction SRS (5 x 5 Gy) is a safe treatment option associated with good local control and improved cranial nerve symptoms for patients with a skull base metastasis involving the anterior visual pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prescription isodose distribution in axial and coronal views of a skull base metastasis compressing the optic chiasm (contoured in yellow). The planning target volume (contoured in blue) was created by the geometric expansion of tumour plus 1 mm. The patient was treated with a linear accelerator (LINAC) multi-fraction stereotactic radiosurgery (5 x 5 Gy) with the use of 8 noncoplanar conformal beams. The dose was prescribed to the 87% isodose line normalized to the maximum dose, with a minimum PTV coverage of 98%. The isodose curves showing dose levels delivered to surrounding tissues and adjacent critical structures are represented.
Figure 2
Figure 2
Kaplan-Meier estimate of local control.
Figure 3
Figure 3
Kaplan-Meier estimate of distant disease-free survival.
Figure 4
Figure 4
Kaplan-Meier estimate of overall survival.

Similar articles

Cited by

References

    1. Laigle-Donadey F, Taillibert S, Martin-Duverneuil N, Hildebrand J, Delattre JY. Skull-base metastases. J Neurooncol. 2005;75:63–69. doi: 10.1007/s11060-004-8099-0. - DOI - PubMed
    1. Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, DeSa GM, Donald P, Fliss D, Gullane P, Janecka I, Kamata SE, Kowalski LP, Kraus DH, Levine PA, Dos Santos LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer. 2003;98:1179–1187. doi: 10.1002/cncr.11630. - DOI - PubMed
    1. Preusser M, Berghoff AS, Schadendorf D, Lin NU, Stupp R. Brain metastasis: opportunity for drug development? Curr Opin Neurol. 2012;25:786–794. doi: 10.1097/WCO.0b013e328359320d. - DOI - PubMed
    1. Vikram B, Chu FC. Radiation therapy for metastases to the base of the skull. Radiology. 1979;130:465–468. - PubMed
    1. Greenberg HS, Deck MD, Vikram B, Chu FC, Posner JB. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology. 1981;31:530–537. doi: 10.1212/WNL.31.5.530. - DOI - PubMed

LinkOut - more resources